A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma (original) (raw)

Access this article

Log in via an institution

Subscribe and save

• Starting from 10 chapters or articles per month
• Access and download chapters and articles from more than 300k books and 2,500 journals
• Cancel anytime View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

1. Boring C, Squires TS, Tong T, Montgomery S: Cancer statistics 1994. Ca 44:7–26, 1994
   CAS Google Scholar
2. Brennan MF, Kinsella T, Casper E: Cancer of the pancreas. In: VT DeVita Jr, S Hellman, SA Rosenberg (eds.) Cancer: Principles and Practice of Oncology. Third edition. JB Lippincott Company, Philadelphia (1939) pp 849–882
   Google Scholar
3. Cullinan S, Moertal CG, Wieand HS, et al: A phase III on the therapy of advanced pancreatic cancer. Cancer 65:2207–2212, 1990
   Article PubMed CAS Google Scholar
4. Cullinan SA, Moertal CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinomas. JAMA 253:2061–2067, 1985
   Article PubMed CAS Google Scholar
5. Schein PS, Lavin PT, Moertel CG, et al.: Randomized phase II clinical trial of Adriamycin in advanced measurable pancreatic carcinoma: A Gastrointestinal Tumor Study Group report. Cancer 42:19, 1978
   Article PubMed CAS Google Scholar
6. Wils J, Bleiberg H, Blijham G, et al. Phase II study of epirubicin in advance adenocarcinoma of the pancreas. Eur J cancer Clin Oncol 21:191, 1985
   Article PubMed CAS Google Scholar
7. Bitran JD, Dresser RK, Kozloff MF, et al.: Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin and mitomycin-C (FAM). Cancer Treat Rep 63:2049–2051, 1979
   PubMed CAS Google Scholar
8. Smith FP, Hoth DF, Levin B, et al.: 5-Fluorouracil, adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014–2018, 1980
   Article PubMed CAS Google Scholar
9. Cordon-Cardo C, O’Brien J: The multidrug resistance phenotype in human cancer. Important Advances in Oncology 1991. (JB Lippincott Comp. NY, Ed: DeVita V, Helman S, Rosenberg SA), 19–38, 1991
10. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285–1287, 1983
    Article PubMed CAS Google Scholar
11. Thierry AR, Jorgensen TJ, Forst D, et al.: Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Commun 1:311–316, 1989
    PubMed CAS Google Scholar
12. Oudard S, Thierry A, Jorgensen TJ, Rahman A: Sensitization of multidrug resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28:259–265, 1991
    PubMed CAS Google Scholar
13. Rahman A, Treat J, Roh J-K, et al.: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093–1100, 1990
    PubMed CAS Google Scholar
14. Gabizon A, Peretz T, Sulkes A, et al.: Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Clin Oncol 25:1795–1803, 1989
    Article CAS Google Scholar
15. Currie VE, Muindi JA, Young CW: A phase I and comparative pharmacologic study of standard and liposome-encapsulated doxorubicin (Dox and Lipodox). Proc Amer Assoc Cancer Res 32:1197, 1991
    Google Scholar
16. Cowens JW, Creaven PJ, Greco WR, Brenner DE, et al.: Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 53:2796–2802, 1993
    PubMed CAS Google Scholar
17. Kaye SN: Liposomes-Problems and promise as selective drug carriers. Cancer Treat Rev 8:27–50, 1981
    Article PubMed CAS Google Scholar
18. Weinstein JN: Liposomes as drug carriers in cancer therapy. Cancer Treat Rep 68:127–135, 1984
    PubMed CAS Google Scholar
19. Rahman A, Fumagalli A, Barbieri B, et al.: Antitumor and toxicity evaluation of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother Pharmacol 16:22–27, 1986
    PubMed CAS Google Scholar
20. Rahman A, Ganje A, Neefe J: Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother Pharmacol 16:28–34, 1986
    PubMed CAS Google Scholar
21. Gabizon A, Goren D, Fuks Z, et al.: Superior therapeutic activity of liposome-associated Adriamycin in a murine metastatic tumor model. Br J Cancer 51:681–689, 1985
    PubMed CAS Google Scholar
22. Mayhew EG, Goldrosen MH, Vaage J, et al.: Effects of liposome-entrapped doxorubicin on liver metastases in mouse colon carcinomas 26 and 38. J Natl Cancer Inst 78:707–713, 1987
    PubMed CAS Google Scholar
23. Gabizon A, Dagan A, Goren D, et al.: Liposomes as_in vivo_ carriers of Adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 42:4734–4739, 1982
    PubMed CAS Google Scholar
24. Thierry AR, Vige D, Dritischillo, Rahman A: Modulation of multidrug resistance by liposomally encapsulated doxorubicin in two human MDR cell lines. Proc Am Assoc Cancer Res 32:2214, 1991
    Google Scholar
25. Warren L, Jardillier JC, Malarska A, Akeli MG: Increased accumulation of drugs in multidrug-resistant cell induced by liposomes. Cancer Res 52:3241–3245, 1992
    PubMed CAS Google Scholar
26. Treat J, Greenspan A, Forst D, et al.: Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. J Natl Cancer Inst 82:1706–1710, 1990
    Article PubMed CAS Google Scholar
27. Storm G, Roerdink FH, Steerenberg PA, et al.: Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res 47:3366–3372, 1987
    PubMed CAS Google Scholar

Download references